Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, AIST Partner Up for Joint Research for IT Drug-Discovery Technologies
July 24, 2015
- Kyowa Kirin to File for Regulatory Approval of Psoriasis Treatment Brodalumab
July 24, 2015
- EU Approves Opdivo for Squamous NSCLC: BMS
July 23, 2015
- Cell Transplantation Using iPS Cell-Derived Renal Progenitors Effective for Acute Kidney Injury in Mice: Kyoto Univ., Astellas
July 23, 2015
- PIII Study of Opdivo in Renal Cell Carcinoma Ends Early Based on Favorable Results: Ono, BMS
July 23, 2015
- JCR, Eisai Collaborate for Blood-Brain Barrier Penetration Technology
July 22, 2015
- Ono Files Opdivo for Non-Squamous NSCLC
July 22, 2015
- Japanese Contract Manufacturing Market Grows to 290 Billion Yen in FY2013: Yano Research
July 21, 2015
- Eisai to Transfer US Subsidiary Plant to Biogen
July 21, 2015
- GSK, Pola Pharma Join Hands for Marketing of Acne Vulgaris Treatment Duac
July 21, 2015
- Kyowa Kirin R&D Exec Lauds Sakigake System, but Calls for More Incentives
July 17, 2015
- Deltyba Effective in Extensively Drug-Resistant Tuberculosis: Otsuka
July 17, 2015
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- Quintiles to Make Full-Fledge Entry into Regenerative Medicine, by Opening New Office in Kobe
July 16, 2015
- Sumitomo Dainippon Ties Up with Servier for Commercialization of Latuda in Australia
July 16, 2015
- Takeda Files NDA for Novel Proteasome Inhibitor Ixazomib in US
July 16, 2015
- As 80% Era Looms, 3 Generic Majors Will Emerge as Dominant Suppliers: Sawai
July 16, 2015
- Kowa Grants Chugai Exclusive Marketing Rights in Japan for Peretinoin for Prevention of Recurrence of HCC
July 15, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…